In Reply We thank Marx and colleagues for their thoughtful comment on our recent article investigating the prevalence of posttraumatic stress disorder (PTSD) in postacute COVID-19 illness.1 We fully agree with the authors on the importance of assessing COVID-19–associated PTSD through the criterion-standard Clinician Administered PTSD Scale for DSM-5 (CAPS-5).2 Based on the CAPS-5, we found a 30.2% prevalence of PTSD in patients after acute COVID-19. Our results partly match the pooled PTSD prevalence of 21.94% (95% CI, 9.37-43.31) found in the meta-analysis by Cénat et al,3 which Marx and colleagues cited. However, this meta-analysis3 pooled actual patients with individuals from the general population. Hence, the higher PTSD prevalence found in our study in patients who experienced acute COVID-19 illness is not surprising and in line with the rate of 32.2% (95% CI, 23.7-42.0) reported by Rogers et al4 in postacute patients after previous coronavirus epidemics. Because the field is rapidly expanding, it is likely that many studies will be added and used to meta-analyze and synthesize published evidence.